Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Tax Provisions (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Tax Provisions data on record, last reported at $549286.0 in Q3 2025.

  • For Q3 2025, Tax Provisions rose 4896.23% year-over-year to $549286.0; the TTM value through Sep 2025 reached $1.3 million, up 2681.81%, while the annual FY2024 figure was $536815.0, 577.16% up from the prior year.
  • Tax Provisions reached $549286.0 in Q3 2025 per GANX's latest filing, up from $141205.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $549286.0 in Q3 2025 and bottomed at -$8245.0 in Q4 2021.
  • Average Tax Provisions over 5 years is $79161.8, with a median of $14502.0 recorded in 2023.
  • Peak YoY movement for Tax Provisions: plummeted 502.7% in 2021, then skyrocketed 11579.49% in 2025.
  • A 5-year view of Tax Provisions shows it stood at -$8245.0 in 2021, then surged by 1047.3% to $78105.0 in 2022, then crashed by 81.43% to $14502.0 in 2023, then skyrocketed by 3380.47% to $504738.0 in 2024, then grew by 8.83% to $549286.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $549286.0 in Q3 2025, $141205.0 in Q2 2025, and $100509.0 in Q1 2025.